Clinical Trials
14 trialsNCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT05227326 2025-09-18
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
Phase 1 Recruiting
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01154452 2018-08-15
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00005874 2013-12-04
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006357 2012-09-24
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00400569 2012-08-28
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00041249 2012-07-18
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00069940 2010-12-28
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Dana-Farber Cancer Institute
Phase 1 Completed